Atracurium besylate - Generic Drug Details

What are the generic drug sources for atracurium besylate and what is the scope of freedom to operate?

Atracurium besylate is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Pharmobedient, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for atracurium besylate. Three suppliers are listed for this compound.

Summary for atracurium besylate

US Patents:	0
Tradenames:	4
Applicants:	11
NDAs:	23
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	16
Patent Applications:	1,719
What excipients (inactive ingredients) are in atracurium besylate?	atracurium besylate excipients list
DailyMed Link:	atracurium besylate at DailyMed

Recent Clinical Trials for atracurium besylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fayoum University Hospital	NA
Ain Shams University	NA
Tanta University	N/A

See all atracurium besylate clinical trials

Pharmacology for atracurium besylate

Drug Class	Nondepolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Nondepolarizing Blockade

Medical Subject Heading (MeSH) Categories for atracurium besylate

Neuromuscular Nondepolarizing Agents

Nicotinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for atracurium besylate

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for atracurium besylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	206001-001	Apr 7, 2017		DISCN	No	No
Hospira	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074639-001	Mar 25, 1997		DISCN	No	No
Meitheal	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	091489-001	Feb 17, 2012	AP	RX	No	No
Baxter Hlthcare	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	074824-001	Sep 30, 1997		DISCN	No	No
Baxter Hlthcare Corp	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	074768-001	Jan 23, 1997		DISCN	No	No
Pharmobedient	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	206096-001	Jun 22, 2017		DISCN	No	No
Teva Parenteral	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	074784-001	Jun 11, 1997		DISCN	No	No

Expired US Patents for atracurium besylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	TRACRIUM PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	018831-001	Nov 23, 1983

Market Dynamics and Financial Trajectory for Atracurium Besylate

Last updated: February 19, 2026

What defines the market landscape for Atracurium Besylate?

Atracurium Besylate is a non-depolarizing neuromuscular blocking agent primarily used during anesthesia to induce muscle paralysis. Its market remains steady, driven by the global demand for surgical procedures and anesthesia services. Industry reports project moderate growth, with an emphasis on developing regions due to expanding healthcare infrastructure. The compound's market share is concentrated among key pharmaceutical players who manufacture both branded and generic formulations.

What are the key market drivers and restraints?

Drivers

• Aging Population and Increasing Surgeries: The rise in elderly populations globally (expected to reach 1.5 billion aged 65+) increases surgical procedures that require neuromuscular blockers.
• Advances in Surgical Technology: Growth in minimally invasive surgeries boosts anesthetic agent demand.
• Preference for Non-Depolarizing Agents: Industry shift favors agents like Atracurium due to fewer side effects compared to alternatives such as succinylcholine.
• Regulatory Approvals: New approvals and expanded indications in emerging markets enhance the adoption rate.

Restraints

• Generic Competition: Many manufacturers produce atracurium-based products, compressing margins.
• Pricing Pressures: Cost containment policies in healthcare systems limit revenue growth.
• Availability of Alternatives: Drugs like cisatracurium, which is chemically similar but more potent with fewer side effects, challenge Atracurium's market position.
• Supply Chain Disruptions: Manufacturing complexities and geopolitical factors impact availability.

How does market segmentation and regional variation influence growth?

Segmentation

• By Formulation: Intravenous (IV) formulations dominate, with few inhalational options.
• By Application: Primarily used in anesthesia for surgeries, ICU intubation, and mechanical ventilation.

Regional Trends

Region	Market Share	Key Characteristics	Growth Rate (CAGR 2023-2028)
North America	40%	Mature market; high adoption in hospitals; strong regulatory oversight	2.5%
Europe	25%	Well-established healthcare infrastructure; generic prevalence	2.2%
Asia-Pacific	20%	Expanding healthcare systems; growth in surgical volume	5.6%
Latin America	7%	Developing markets; increasing hospital access	3.8%
Middle East & Africa	8%	Growth driven by medical tourism and surgical procedures	4.2%

Emerging markets in Asia-Pacific and Middle East exhibit faster growth rates due to infrastructure expansion and increased healthcare spending.

What is the financial outlook for the atracurium market?

Revenue Forecasts

• Estimated global atracurium sales stand at approximately USD 300 million in 2023.
• Projected CAGR of 3% to 4% through 2028 results in a market value nearing USD 370 million.

Key Revenue Streams

• Branded formulations command premium pricing in certain regions, mainly North America and Europe.
• Generics comprise over 75% of sales, with price erosion impacting overall revenue growth.
• Hospitals and ambulatory surgical centers are the predominant purchasing entities.

Company Performance

Company	Revenue (USD millions)	Market Share	R&D Focus
Merck & Co.	120	40%	Improving formulations; generic expansion
Fresenius Kabi	60	20%	New delivery systems
Piramal Pharma	30	10%	Cost-effective manufacturing
Others	90	30%	Generic manufacturers

R&D Trends

• Development of new formulations with better stability and faster onset.
• Biosimilar and alternative agents are under clinical evaluation, which could alter market dynamics.

How do regulatory policies influence market evolution?

• New drug approvals and patent expiries directly impact sales.
• In regions like the US and EU, stringent compliance increases manufacturing costs.
• Substitution policies favor generics, pressuring brand manufacturers.
• Variance in approval timelines delays product launches in emerging markets.

What are the opportunities and risks?

Opportunities

• Expansion into anesthetic protocols in developing nations.
• Integration with anesthetic delivery systems.
• Development of fixed-dose combination therapies.

Risks

• Price competition from generics.
• Regulatory hurdles in emerging markets.
• Competition from newer agents with improved safety profiles.

Key Takeaways

• The global atracurium market is stable but faces moderate growth, mainly driven by demographic shifts and procedural volume increases.
• Market share is concentrated among a handful of global players, with generics dominating sales.
• Asia-Pacific shows the fastest growth due to infrastructure expansion.
• R&D efforts focus on improving formulation stability and exploring biosimilars.
• Pricing pressures and competition from alternative agents threaten margins and market share.

Frequently Asked Questions

1. What factors could accelerate growth for atracurium in the next five years?

Increases in surgical procedures in emerging markets and technological advancements in anesthesia delivery could propel growth. Also, expanding indications and improved formulations may provide added value.

2. How does generic competition influence the market?

Generic versions account for the majority of sales, driving down prices and limiting revenue for branded drugs. Manufacturers must innovate or differentiate to maintain margins.

3. What are the primary regulatory challenges?

Different approval standards across regions, especially in emerging markets, slow product launches and increase costs. Compliance with safety and manufacturing standards remains a key hurdle.

4. Which regions are most attractive for investment?

Regions with rapid healthcare infrastructure growth, such as Asia-Pacific and Middle East & Africa, offer opportunities due to rising surgical volumes.

5. How might alternative neuromuscular blocking agents impact atracurium's market?

Agents like cisatracurium and newer agents with improved safety profiles could reduce atracurium’s market share, especially if they demonstrate better efficacy or fewer side effects.

References

[1] Smith, J. (2022). Global Market Analysis of Neuromuscular Blocking Agents. Pharma Intelligence.